{"entity":{"id":"nct06308406","kind":"trial","name":"A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is unknown.","summary":"The registry lists NCT06308406 as unknown, last updated 2024-04-11. Enrolment is 54 planned participants, an estimate. Interventions: Bevacizumab； HRS-1167. Primary measures include The number of subjects with dose-limiting toxicity (DLT); Determination of Recommended Phase II dose (RP2D). No results are posted in the registry; this does not exclude separate publications.","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06308406","url":"https://clinicaltrials.gov/study/NCT06308406"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["hrs-1167"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06308406","phase":"1/2","setting":"A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","started":"2024-03-15","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06308406/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"hrs-1167","kind":"drug","name":"HRS-1167","route":"/drugs/hrs-1167/"}]}}